CEO of Recursion Pharma Quietly Offloads 22,000 Shares as Market Stays Flat

Insider Selling on a Quiet Day – What It Signals for Recursion

The latest Rule 4 filing shows CEO and President Khan Najat selling 22,408 shares of Recursion’s Class A common stock at a weighted average price of $3.52. The trade was executed under a Rule 10b5‑1 plan that was adopted last September, and the sale was reported in the week of September 8, 2026. On a day when the share price dipped only 0.02 % to $3.215, the sale adds another chapter to a pattern of relatively modest, systematic sell‑offs that have characterized Najat’s insider activity over the past year.

A Pattern of Structured Unloading

Since early 2026, Najat has sold roughly 150,000 shares in nine discrete trades, averaging $3.30–$3.58 per share, while maintaining a sizeable position of about 2.3 million shares. The most recent sale is consistent with the 10‑month average price of $3.37 and follows a string of smaller sales in June, August, and March. Importantly, none of the transactions involve large block trades that would have moved the stock significantly; the average trade size is under 25 k shares, and the Rule 10b5‑1 plan provides a pre‑determined schedule that protects the executive from allegations of market‑timing or insider advantage.

What This Means for Investors

For investors, the key takeaway is that the CEO’s selling does not appear to be a sudden sign of distress. The plan’s existence, coupled with the fact that the sales have been spread over months and executed at market‑congruent prices, suggests that Najat is likely liquidating a portion of her personal portfolio rather than reacting to company fundamentals. The broader insider picture, however, is more mixed. While other executives—including CFO Taylor Ben R and Chief Scientific Officer Hallett David—have also sold shares during the same period, the volume remains modest relative to the 184 million‑dollar market cap.

A Profile of Khan Najat

Najat’s insider history paints a picture of a cautious yet active shareholder. She entered Recursion as Chief R&D Commercial Officer in 2035, holding a growing block of stock options that she has since exercised and retained. Since becoming CEO in 2026, she has maintained a steady position while periodically selling to diversify her personal wealth. Her trades have averaged just over $3.30 and are executed under a pre‑approved plan, indicating a disciplined approach that balances personal liquidity needs with a long‑term commitment to the company. Unlike some peers who have dumped large blocks amid earnings disappointments, Najat’s pattern suggests confidence in Recursion’s AI‑driven drug discovery pipeline, even as the stock has endured a 34 % year‑to‑date decline.

Looking Forward

With the market still in a trough—52‑week lows at $2.77 and a nearly 9 % weekly loss—investors may view Najat’s orderly sales as a neutral signal. The company’s ongoing research and its position in the AI‑driven biotech niche remain attractive, but the lack of recent upside momentum and a negative price‑earnings ratio of –3.41 temper enthusiasm. In short, the insider activity does not appear to undermine confidence, but it does underscore the need for investors to monitor both corporate performance and the timing of future equity plans as Recursion navigates a volatile sector.